Installed-base annuity
Capital systems are often placed at thin margins to drive high-margin disposable and service revenue for years afterward.
MEDICAL TECHNOLOGY / STRATEGY + OPERATIONS
Hospital buyers squeeze price while regulatory and supply costs rise
Medical technology companies design, manufacture and sell devices, implants, capital equipment and disposables used in hospitals, surgery centers and clinics. They earn revenue from capital sales, procedure-linked consumables and service contracts, and profit depends on pricing power with hospital buyers, manufacturing cost and the cost of field sales and clinical support.
P&L OPERATING MODEL
See how commercial and operating decisions move the P&L.
Select a sector and switch between the profit bridge and the underlying cost structure. The baseline is indexed to revenue so the economics remain comparable.
INDUSTRY P&L BRIDGEMEDICAL TECHNOLOGY / REVENUE INDEXED TO 100
REVENUE INDEX100.0 → 104.0Commercial growth case
OPERATING PROFIT18.0 → 25.3+7.3 points
MARGIN18.0% → 24.3%Combined opportunity case
18.0Baseline profit
+4.0Revenue growth
+1.0Cost of goods
+1.0Sales & field clinical
+0.3R&D & clinical studies
+0.5Quality, regulatory & G&A
+0.5Distribution & loaner sets
25.3With Aryo profit
REVENUEPrice, mix, retention, channel, product, and market focus
COSTProcurement, labor, throughput, footprint, complexity, and overhead
DATACompany actuals, industry benchmarks, operating signals, and measured deltas
HOW THE BUSINESS WORKS
How medical technology companies make money.
The revenue streams and structural traits that decide where profit is made and lost in this sector.
Revenue model
- Implant and device sales, often through consignment and case coverage
- Capital equipment sales or placements tied to consumable commitments
- Recurring disposables and procedure kits
- Service contracts, software and upgrades on the installed base
Field sales intensity
Reps and clinical specialists support cases in the operating room, so selling cost is high and tied closely to procedure volume.
Consignment inventory
Loaner sets and consigned implants sitting in hospitals tie up large amounts of inventory and cash.
Regulatory burden
FDA clearances, EU MDR certification and quality system requirements add cost and time to every new product and design change.
WHAT TO WATCH
The measures and pressures that matter now.
Five numbers management should review every month, and what is changing in the sector.
- 1
Procedure volume growth
Drives disposable and implant revenue and indicates share movement.
- 2
Average selling price trend
Measures pricing pressure from GPOs, IDNs and competitors.
- 3
Gross margin by product line
Shows the combined effect of mix, manufacturing cost and pricing.
- 4
Field inventory turns
Indicates how much capital is tied up in consigned and loaner inventory.
- 5
Selling cost per covered case
Tracks field efficiency as procedure volume grows.
Pressures right now
- Tariffs on components and finished devices sourced from China and other countries are raising manufacturing costs.
- Hospital capital budgets remain tight because of labor costs and payer pressure, lengthening sales cycles for equipment.
- China’s volume-based procurement continues to cut prices for device makers selling into that market.
- GLP-1 drugs have raised questions about long-term demand for some bariatric, sleep apnea and cardiometabolic devices.
WHERE THE VALUE IS
Where medical technology companies find the most value.
The changes that usually move the P&L most in this sector, and the service that delivers each one.
Contract and price management
Manage contract tiers and price floors so GPO and IDN agreements do not erode price across the base.
Pricing strategy & discount controlField force model
Match rep and clinical specialist coverage to case volume and account potential.
Sales effectiveness & pipelineManufacturing cost
Reduce scrap, rework and sole-source exposure in the highest-volume product lines.
Process & productivity improvementField inventory
Cut loaner set counts and consignment levels while protecting case coverage.
Supply chain, inventory & S&OPQuestions leaders in medical technology should be able to answer
- How much of our price erosion comes from contract structure rather than competition?
- Is our field team deployed where case volume and growth potential are highest?
- Which sole-source components could stop production, and what would a second source cost?
SECTORS IN THIS INDUSTRY
One industry architecture, adapted to the operating context.
The same strategic question behaves differently by customer, product, asset, regulation, channel, and business model.
Put your numbers behind the decision.
New product launch hurdle
Calculate the contribution break-even while separating inventory purchasing cash from cost of sold units.
Inventory turns & cashConnect inventory turns, days on hand, and a target stocking level.
Dual-sourcing resilienceCompare probability-weighted disruption reduction with supplier premiums and qualification costs.